BioMarin plans FDA filing in Q3 2026 for Voxzogo in hypochondroplasia

Biomarin

Biomarin

BMRN

0.00
  • BioMarin plans to file a supplemental NDA with the FDA in Q3 2026 to expand VOXZOGO’s label to children with hypochondroplasia, following positive Phase 3 data.
  • The CANOPY-HCH-3 trial met its primary endpoint, showing a 2.33 cm/year improvement in annualized growth velocity versus placebo at week 52.
  • Submissions to the EMA and other regulators are expected to follow.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605201620PR_NEWS_USPR_____SF64695) on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.